Somesh Chattopadhyay

First FDA Approval of Dual Anti-HER2 Regimen: Pertuzumab in Combination with Trastuzumab and Docetaxel for HER2-Positive Metastatic Breast Cancer

R. Pazdur, B. Rellahan, P. Cortazar, 2013, Clinical Cancer Research.

Probabilistic recovery of neuroendocrine pulsatile, secretory and kinetic structure: An alternating discrete and continuous scheme

D. M. Keenan, D. Keenan, J. Veldhuis, 2008 .

Sorafenib for the treatment of unresectable hepatocellular carcinoma.

R. Pazdur, R. Justice, R. Sridhara, 2009, The oncologist.

Composite model of time-varying appearance and disappearance of neurohormone pulse signals in blood.

D. M. Keenan, Johannes D Veldhuis, J. Veldhuis, 2005, Journal of theoretical biology.

Bayesian Methods in Human Drug and Biological Products Development in CDER and CBER

Alexei C Ionan, Alexei C. Ionan, M. Rothmann, 2022, Therapeutic Innovation & Regulatory Science.

Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC).

R. Pazdur, R. Justice, R. Sridhara, 2010, The oncologist.

Vandetanib for the Treatment of Symptomatic or Progressive Medullary Thyroid Cancer in Patients with Unresectable Locally Advanced or Metastatic Disease: U.S. Food and Drug Administration Drug Approval Summary

C. Garnett, R. Pazdur, Y. Moon, 2012, Clinical Cancer Research.

On Bayesian Analysis and Hypothesis Testing in the Determination of Bioequivalence

Donald J. Schuirmann, S. Chow, Somesh Chattopadhyay, 2019, Clinical pharmacology and therapeutics.